TWINGEN - protocol for an observational clinical biobank recall and biomarker study to identify individuals with high risk of Alzheimer's disease.

Autor:	Vuoksimaa E; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Saari TT; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Aaltonen A; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Aaltonen S; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Herukka SK; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.; Department of Neurology, Neurocenter, Kuopio University Hospital, Kuopio, Finland., Iso-Markku P; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Kokkola T; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland., Kyttälä A; Finnish Institute for Health and Welfare, Helsinki, Finland., Kärkkäinen S; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland., Liedes H; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.; VTT Technical Research Centre of Finland Ltd., Oulu, Finland., Ollikainen M; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Palviainen T; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Ruotsalainen I; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.; VTT Technical Research Centre of Finland Ltd., Espoo, Finland., Toivola A; Finnish Institute for Health and Welfare, Helsinki, Finland., Urjansson M; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Vasankari T; UKK Institute for Health Promotion Research, Tampere, Finland.; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Vähä-Ypyä H; UKK Institute for Health Promotion Research, Tampere, Finland., Forsberg MM; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.; VTT Technical Research Centre of Finland Ltd., Kuopio, Finland., Hiltunen M; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland., Jalanko A; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Kälviäinen R; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.; Department of Neurology, Neurocenter, Kuopio University Hospital, Kuopio, Finland., Kuopio T; Central Finland Biobank, Central Finland Health Care District, Jyväskylä, Finland., Lähteenmäki J; VTT Technical Research Centre of Finland Ltd., Espoo, Finland., Nyberg P; Biobank Borealis of Northern Finland, Oulu University Hospital, Wellbeing Services county of North Ostrobothnia, Oulu, Finland.; Translational Medicine Research Unit, University of Oulu, Oulu, Finland., Männikkö M; Arctic Biobank, Infrastructure for Population Studies, Faculty of Medicine, University of Oulu, Oulu, Finland., Serpi R; Biobank Borealis of Northern Finland, Oulu University Hospital, Wellbeing Services county of North Ostrobothnia, Oulu, Finland., Siltanen S; Finnish Clinical Biobank Tampere, Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland., Palotie A; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.; Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.; The Stanley Center for Psychiatric Research and Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kaprio J; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Runz H; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.; Translational Sciences, Biogen, Cambridge, MA, USA., Julkunen V; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.; Department of Neurology, Neurocenter, Kuopio University Hospital, Kuopio, Finland.
Jazyk:	angličtina
Zdroj:	MedRxiv : the preprint server for health sciences [medRxiv] 2023 Nov 07. Date of Electronic Publication: 2023 Nov 07.
DOI:	10.1101/2023.11.03.23298018
Abstrakt:	Introduction: A better understanding of the earliest stages of Alzheimer's disease (AD) could expedite the development or administration of treatments. Large population biobanks hold the promise to identify individuals at an elevated risk of AD and related dementias based on health registry information. Here, we establish the protocol for an observational clinical recall and biomarker study called TWINGEN with the aim to identify individuals at high risk of AD by assessing cognition, health and AD-related biomarkers. Suitable candidates were identified and invited to participate in the new study among Finnish biobank donors according to TWINGEN study criteria. Methods and Analysis: A multi-center study (n=800) to obtain blood-based biomarkers, telephone-administered and web-based memory and cognitive parameters, questionnaire information on lifestyle, health and psychological factors, and accelerometer data for measures of physical activity, sedentary behavior and sleep. A sub-cohort are being asked to participate in an in-person neuropsychological assessment (n=200) and wear an Oura ring (n=50). All participants in the TWINGEN study have genome-wide genotyping data and up to 48 years of follow-up data from the population-based older Finnish Twin Cohort (FTC) study of the University of Helsinki. TWINGEN data will be transferred to Finnish Institute of Health and Welfare (THL) biobank and we aim to further to transfer it to the FinnGen study where it will be combined with health registry data for prediction of AD. Ethics and Dissemination: This recall study consists of FTC/THL/FinnGen participants whose data were acquired in accordance with the Finnish Biobank Act. The recruitment protocols followed the biobank protocols approved by Finnish Medicines Agency. The TWINGEN study plan was approved by the Ethics Committee of Hospital District of Helsinki and Uusimaa (number 16831/2022). THL Biobank approved the research plan with the permission no: THLBB2022_83. Competing Interests: Competing interests statement AP is the Chief Scientific Officer of the FinnGen project that is funded by thirteen pharmaceutical companies. HR was a full-time employee of Biogen during study planning and manuscript drafting and has stocks at Merck & Co. and Biogen Inc. MMF has received development funding from the Regional Council of Northern Savo and Business Finland for a data-driven tool related to memory disorders and healthcare decision tools, Charles River DRS Finland Ltd. and Orion Pharma have donated equipment for nonclinical cognition testing at the University of Eastern Finland. PI-M has received funding from Orion Research Foundation and Helsinki Biomedicum Foundation outside the present work. RK declares funding paid to the institution from Academy of Finland, Government research funding, Saastamoinen Foundation, Vaajasalo foundation and Jane and Aatos Erkko foundation outside the present work; consulting fees from Orion Pharma; payment or honoraria from Angelini Pharma, Jazz Pharma, Lundbeck, Eisai, Orion Pharma, OmaMedical, Takeda, UCB; participation in monitoring or advisory board from Marinus Pharma and UCB; and leadership or fiduciary role in European Academy of Neurology Epilepsy scientific panel management group, European Epilepsy Reference network Epicare Steering Group and International League Against Epilepsy Career Development Commission. RS declares stocks or stock options at Orion Pharma. S-KH declares payment or honoraria and support for attending meetings or travel from Roche, consulting fees and participation in monitoring or advisory board from Novartis. TK declares payment or honoraria from Novartis Finland and Bayer Nordic SE. The authors declare no other competing financial or non-financial Interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu